SCHEMBL25314946

SCHEMBL25314946

CC(C)(C)OC(=O)N1CCN(c2ccc(N)nc2F)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.50
SMARCA2 P51531 1/20 0.49
SMARCA4 P51532 1/20 0.49
PBRM1 Q86U86 1/20 0.49
ADORA2A P29274 1/20 0.48
ADORA1 P30542 1/20 0.48
CKS1B P61024 2/20 0.46
SKP1 P63208 2/20 0.46
SKP2 Q13309 2/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
PTPN11 Q06124 1/20 0.46
BACE1 P56817 2/20 0.45
GPR119 Q8TDV5 3/20 0.44
PIK3CA P42336 2/20 0.44
GBA1 P04062 1/20 0.43
ACHE P22303 1/20 0.43
KIT P10721 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31006176 1.00 MAP4K4 (0.50) MAP4K4SMARCA2SMARCA4PBRM1ADORA2A
SCHEMBL31727637 0.87 SCN9A (0.41) MAP4K4SMARCA2SMARCA4PBRM1ADORA2A
SCHEMBL30418929 0.86 MAP4K4 (0.51) MAP4K4SMARCA2SMARCA4PBRM1ADORA2A
SCHEMBL21698657 0.86 MAP4K4 (0.51) MAP4K4SMARCA2SMARCA4PBRM1ADORA2A
SCHEMBL31006180 0.84 MAP4K4 (0.49) MAP4K4SMARCA2SMARCA4PBRM1ADORA2A
SCHEMBL25189993 0.84 MAP4K4 (0.49) MAP4K4SMARCA2SMARCA4PBRM1ADORA2A
SCHEMBL30218618 0.84 BACE1 (0.48) MAP4K4SMARCA2SMARCA4PBRM1CKS1B
SCHEMBL25322195 0.84 BACE1 (0.48) MAP4K4SMARCA2SMARCA4PBRM1CKS1B
SCHEMBL25314686 0.82 MAP4K4 (0.48) MAP4K4SMARCA2SMARCA4PBRM1ADORA2A
SCHEMBL31006182 0.82 MAP4K4 (0.48) MAP4K4SMARCA2SMARCA4PBRM1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12521440-B2 Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use BEONE MEDICINES I GMBH (CH) 2026-01-13 US disclosed
US-20250205345-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEIGENE SWITZERLAND GMBH (CH) 2025-06-26 US disclosed
US-20240366769-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEIGENE SWITZERLAND GMBH (CH) 2024-11-07 US disclosed
WO-2023125908-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEIGENE, LTD. (KY) 2023-07-06 WO disclosed
WO-2023125908-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEIGENE, LTD. (KY) 2023-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366769-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BTK, CBL, LYN MAP4K4 1247/4885SMARCA2 2614/4885SMARCA4 2838/4885
US-20250205345-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BTK, CBL, LYN MAP4K4 1247/4885SMARCA2 2614/4885SMARCA4 2838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.